FDA Declares Tirzepatide Shortage Resolved, Narrowing Path for Compounders
Tuesday, June 9, 2026 — The U.S. Food and Drug Administration has determined that the nationwide shortage of tirzepatide injection, a dual GIP/GLP-1 receptor drug sold by Eli Lilly, has been resolved, the agency's Center for Drug Evaluation and Research said. The shortage had persisted since 2022 amid surging demand for weight-management and type 2 diabetes treatments.
The designation carries significant implications for compounding pharmacies that had been supplying copies of tirzepatide under federal shortage exemptions.
Regulation leads the story
Under federal law, compounders may prepare versions of certain drugs while they appear on the FDA's drug shortages list. With tirzepatide now removed from that list, pharmacies operating under Section 503A and outsourcing facilities under Section 503B lose that legal foothold for tirzepatide compounding unless other regulatory conditions apply.
The FDA's compounding compliance page lists recent inspections, recalls, and enforcement actions affecting both categories of compounders. The agency has also been issuing warning letters to pharmacies and facilities that it says compounded drug products in violation of federal standards.
Compounding pharmacies face a narrower path
The Alliance for Pharmacy Compounding and the Outsourcing Facilities Association, two trade groups representing 503A and 503B compounders respectively, have previously argued that compounding plays a critical role during shortages. Both organizations' news feeds are likely to address the FDA's tirzepatide determination.
Industry context pages from the National Association of Boards of Pharmacy provide verification resources for consumers seeking licensed pharmacies.
Trial records keep retatrutide in focus
ClinicalTrials.gov registrations for newer incretin-class peptides — including Eli Lilly's triple-agonist retatrutide and Novo Nordisk's fixed-dose combination cagrisema — continue to grow. Trial records show active and recruiting studies spanning obesity, metabolic-associated steatohepatitis, and obstructive sleep apnea.
Preprint servers and indexed literature on PubMed show ongoing early-stage research into next-generation peptide therapeutics, though these results have not yet undergone full peer review.
Sports rules remain separate
The World Anti-Doping Agency's prohibited list covers peptide hormones, growth factors, and related mimetics. Athletes and their clinicians should consult the current WADA list directly to verify the status of any specific peptide or incretin agent, as restrictions can vary by substance and context.
